Literature DB >> 20494310

Role of breast MR imaging in neoadjuvant chemotherapy.

H Carisa Le-Petross1, Nola Hylton.   

Abstract

Neoadjuvant chemotherapy is now widely used in the management of locally advanced breast cancer (LABC). Early initiation of systemic therapy can improve overall and disease-free survival for patients with LABC or inflammatory cancer. MR imaging with intravenous contrast and advanced MR imaging techniques provide new opportunities for assessing tumor morphologic changes, tumor vascularity, tumor cellularity, and tumor metabolic features. MR imaging is more reliable than the conventional methods in the assessment of tumor size and vascularity changes during and after chemotherapy. The addition of advanced imaging techniques to further characterize tumor cellularity and metabolic features appears promising. However, there is still no consensus on the role of MR imaging for assessing response to neoadjuvant chemotherapy or on a standardized MR imaging examination in patients receiving neoadjuvant chemotherapy. Copyright 2010. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20494310     DOI: 10.1016/j.mric.2010.02.008

Source DB:  PubMed          Journal:  Magn Reson Imaging Clin N Am        ISSN: 1064-9689            Impact factor:   2.266


  8 in total

Review 1.  Proton magnetic resonance spectroscopy in oncology: the fingerprints of cancer?

Authors:  Roberto García-Figueiras; Sandra Baleato-González; Anwar R Padhani; Laura Oleaga; Joan C Vilanova; Antonio Luna; Juan Carlos Cobas Gómez
Journal:  Diagn Interv Radiol       Date:  2016 Jan-Feb       Impact factor: 2.630

2.  Evaluation of Neoadjuvant Chemotherapy Response with Dynamic Contrast Enhanced Breast Magnetic Resonance Imaging in Locally Advanced Invasive Breast Cancer.

Authors:  Naciye Sinem Gezer; Özge Orbay; Pınar Balcı; Merih Guray Durak; Binnaz Demirkan; Serdar Saydam
Journal:  J Breast Health       Date:  2014-04-01

3.  Predicting breast tumor response to neoadjuvant chemotherapy with diffuse optical spectroscopic tomography prior to treatment.

Authors:  Shudong Jiang; Brian W Pogue; Peter A Kaufman; Jiang Gui; Michael Jermyn; Tracy E Frazee; Steven P Poplack; Roberta DiFlorio-Alexander; Wendy A Wells; Keith D Paulsen
Journal:  Clin Cancer Res       Date:  2014-10-07       Impact factor: 12.531

4.  ¹⁸F-FLT PET/CT as an imaging tool for early prediction of pathological response in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy: a pilot study.

Authors:  Flavio Crippa; Roberto Agresti; Marco Sandri; Gabriella Mariani; Barbara Padovano; Alessandra Alessi; Giulia Bianchi; Emilio Bombardieri; Ilaria Maugeri; Mario Rampa; Maria Luisa Carcangiu; Giovanna Trecate; Claudio Pascali; Anna Bogni; Gabriele Martelli; Filippo de Braud
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-02-12       Impact factor: 9.236

Review 5.  The Role of (18)F-FDG PET/CT and MRI in Assessing Pathological Complete Response to Neoadjuvant Chemotherapy in Patients with Breast Cancer: A Systematic Review and Meta-Analysis.

Authors:  Qiufang Liu; Chen Wang; Panli Li; Jianjun Liu; Gang Huang; Shaoli Song
Journal:  Biomed Res Int       Date:  2016-02-15       Impact factor: 3.411

6.  Assessment of early tumor response to cytotoxic chemotherapy with dynamic contrast-enhanced ultrasound in human breast cancer xenografts.

Authors:  Jian-Wei Wang; Wei Zheng; Ji-Bin Liu; Yao Chen; Long-Hui Cao; Rong-Zhen Luo; An-Hua Li; Jian-Hua Zhou
Journal:  PLoS One       Date:  2013-03-01       Impact factor: 3.240

7.  Breast DCE-MRI Kinetic Heterogeneity Tumor Markers: Preliminary Associations With Neoadjuvant Chemotherapy Response.

Authors:  Ahmed Ashraf; Bilwaj Gaonkar; Carolyn Mies; Angela DeMichele; Mark Rosen; Christos Davatzikos; Despina Kontos
Journal:  Transl Oncol       Date:  2015-06       Impact factor: 4.243

8.  The role of PET and MRI in evaluating the feasibility of skin-sparing mastectomy following neoadjuvant therapy.

Authors:  Fatma Umit Malya; Huseyin Kadioglu; Huseyin Kazim Bektasoglu; Zuhal Gucin; Seyma Yildiz; Mehmet Guzel; Ezgi Basak Erdogan; Serap Yucel; Yeliz Emine Ersoy
Journal:  J Int Med Res       Date:  2018-01-14       Impact factor: 1.671

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.